Bio Reports

Akamis Bio Reports Promising Early Efficacy For NG 350A In Rectal Cancer Study

NG-350A combined with chemoradiotherapy demonstrated promising efficacy and a favorable safety profile Composite response rate of 50 percent observed ac...

 April 21, 2026 | News

EpiBiologics Advances Tissue Selective EGFR Degrader EPI 326 Into First In Human Clinical Study

First-in-human study of EPI-326 will evaluate the company’s lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential to ...

 April 21, 2026 | News

Synthetic Design Lab Introduces Logic Gated SYNTHBODY Platform Redefining Precision Protein Therapeutics

SYNTHBODY™ introduces a new class of “smart drugs”: protein therapeutics with built-in, multi-layered logic gates that actively chang...

 April 20, 2026 | News

PFAS Testing Enters A New Era As Solvent Purity And Analytical Discipline Redefine Data Integrity

PFAS analysis has moved from a specialist capability to a core requirement for environmental control and testing laboratories because regulatory values are...

 April 21, 2026 | News

NCIS Leads Multidisciplinary Push To Transform Sarcoma Diagnosis And Care In Singapore

NCIS leads multi-institutional effort to develop expert multidisciplinary guidance to improve sarcoma diagnosis, referrals and outcomes Singapore is stren...

 April 13, 2026 | News

Alar Pharmaceuticals Reports Positive Phase 1 Results For ALA 3000 In Treatment Resistant Depression

By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, impr...

 April 08, 2026 | News

Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer Cases Color...

 April 03, 2026 | News

Takeda Reports Strong Phase 3 Results For Zasocitinib In Plaque Psoriasis

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A signifi...

 March 30, 2026 | News

BrightGene Reports Positive Phase 1 Results For Oral GLP 1 GIP Agonist BGM0504

BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing BrightGene Bio-Medical Technology C...

 March 26, 2026 | News

Celosia Therapeutics Initiates Phase 1b Trial Of CTx1000 Targeting TDP 43 In ALS

CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS Celosia Therapeutics, an Australian biotech company developing advanced gen...

 March 25, 2026 | News

Alphamab Oncology Initiates Phase III Study Of Anbenitamab In HER2 Positive Breast Cancer

Alphamab Oncology announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN02...

 March 25, 2026 | News

Kelun Biotech Reports Strong 2025 Performance With Expanding ADC Pipeline And Commercial Momentum

Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase...

 March 25, 2026 | News

Prestige Biopharma Reports Phase 3 Success For HD204 Demonstrating Clinical Equivalence In Advanced NSCLC

Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung can...

 March 25, 2026 | News

Dizal Reports ZEGFROVY Achieves Superior Progression Free Survival In Phase 3 WU KONG28 Trial For EGFR Exon20ins NSCLC

Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over pla...

 March 23, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close